The Conversation (0)
Hemostemix (TSXV:HEM) is pleased to announce that it has been granted a new patent in the European Union for its patent entitled “Regulating Stem Cells”. As quoted in the press release: “The newly granted patent covers important aspects of Hemostemix’s platform technology and this issuance strengthens our intellectual property portfolio, particularly in the EU. This provides …
Hemostemix (TSXV:HEM) is pleased to announce that it has been granted a new patent in the European Union for its patent entitled “Regulating Stem Cells”.
As quoted in the press release:
“The newly granted patent covers important aspects of Hemostemix’s platform technology and this issuance strengthens our intellectual property portfolio, particularly in the EU. This provides the platform to expand our clinical trials, commercialization and partnering efforts throughout Europe.” states Dr. Ravi Jain, the Company’s Chief Scientific Officer.
“Hemostemix has now had the door opened to expand its technology and operations on a world stage. We are very excited about the opportunities that this patent will allow us to pursue, especially since the European stem cell market is significant and growing,” states Kyle Makofka, Hemostemix’s Chief Executive Officer.
The Company has a broad and growing patent portfolio which covers 5 patent families with over 50 patents issued and pending in several important jurisdictions, including the United States, Canada, Europe, Japan and China.